Oral biologics, solved with intelligent chemistry

BiotechTV

CEO Morten Graugaard discusses the limitations of previous generations of macrocycles and describes what he believes the power is behind the Orbis platform.

European Biotechnology

In the evolving landscape of drug discovery and new design, scientists and pharmaceutical innovators ­continually strive to develop therapies that are both highly ­selective and clinically effective, while addressing targets ­previously deemed “undruggable”. In recent years, macrocycles – a class of large, ring-shaped molecules – have emerged as a compelling solution at the crossroads between ­traditional small molecules and large biologics, offering a blend of high specificity, rich chemical diversity and promising pharma­cological profiles.

Pharmaceutical Executive

In a conversation with Pharmaceutical Executive, Morten Graugaard discussed FDA’s approval of Icotyde as an early validation point for oral biologics, describing it as a meaningful step toward translating the efficacy and target engagement of biologics into more accessible oral formats.

Drug Target Review

New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.

The Bio Report

Orbis Medicines is developing orally available synthetic macrocycles called ⁿCycles that can target diseases typically requiring biologic therapies, offering a novel alternative through its platform technology.